two dog paws in human hands

Using CBD for pets is becoming increasingly popular. Here's a look at whether it's legal in Australia and what CBD can really do for animals.

The medicinal cannabis market is strengthening in Australia, and the country has grand plans of growing, retailing and exporting cannabidiol (CBD) to a keen market.

Among its many applications, CBD is seen as a medicinal aid for people — but what about for pets?

CBD is gaining traction as a remedy for pet ailments as part of an overall treatment plan for chronic illnesses. Read on to learn more about CBD for pets in Australia, from legality to how it can help animals.


What is CBD and is it legal in Australia?

Products containing low doses of CBD are considered safe and legal, provided they have been approved by the Australian Register of Therapeutic Goods (ARTG).

This is a fairly new development — on February 1, 2021, it became legal to purchase low-dose CBD products over the counter at the pharmacist. This change signalled a reclassification of CBD from Australia's Therapeutic Good Administration; it went from being a Schedule 4 product (prescription medicine) to a Schedule 3 product (pharmacist-only medicine).

The catch is that so far no product has yet been approved by the ARTG — unlike other nations that have differing state laws, or even classify CBD as a dietary supplement, in Australia the classification of CBD as medicine has created a lengthy path for approval. Still, CBD is theoretically a legal substance in Australia.

Because of these circumstances, owners who want to source CBD for their pets will need their vet to prescribe the substance. This can be done providing the product to be used meets four conditions:

  1. Cannabidiol comprises 98 percent or more of the total cannabinoid in the preparation.
  2. Any cannabinoids other than cannabidiol must be only those naturally found in cannabis.
  3. The owner must consent to trial an unlicenced and potentially harmful treatment.
  4. There is adequate monitoring of the furry patient's response and any side effects.

The process can be tricky, but there are dedicated businesses set up purely to facilitate the process of obtaining legal medicinal CBD for pets — like CBD Vets Australia.

How can CBD help pets?

Through anecdotal data and information, CBD is thought to be able to assist pets with a number of conditions, such as epilepsy, arthritis, stress and anxiety, chronic pain and nausea; it can even help them sleep.

CBD is an antidote for owners looking to soothe their pets' ailments and keep them both calm and free of pain. As it comes in both capsule and liquid forms, it can be easily mixed in pet food.

In terms of CBD pet products currently available in Australia, animals could access the same CBD oil as humans as of the time of publication.

Importantly, CBD is not to be confused with hemp products. Hemp products, including creams and edible oil, contain extremely low forms of THC cannabis, but are considered to be a safe and legal food product — they are particularly high in omega 3 and six fatty acids.

What's the outlook for Australia's CBD pet products market?

It is early days for the CBD pet market in Australia, and more research is needed on the impacts and effects of CBD on our four-legged companions.

There is positive anecdotal feedback on its benefits, but further information is needed to allow a greater number of vets to feel comfortable prescribing CBD to pets.

The industry has seen growth in medicinal cannabis prescriptions in Australia, and it's possible that the same movement will start to be seen in the pet niche over the coming years, making it a potential avenue for investors to keep an eye on. For now, click the links below for more on Australia's CBD market:

Don't forget to follow @INN_Australia for real-time updates!

Securities Disclosure: I, Ronelle Richards, hold no direct investment interest in any company mentioned in this article.

Featured
Global News
floating us money
vovan / Shutterstock

Joe Mazumdar of Exploration Insights also shared his thoughts on the copper market and how to evaluate copper deposits.

Joe Mazumdar: Good vs. Bad Financings — What to Look for When Juniors Raise Money youtu.be

Raising money is a key challenge for juniors in today's markets — and even when companies are able to secure funds, it's key to remember that not all financings are equal.

Speaking at the Prospectors & Developers Association of Canada (PDAC) convention, Joe Mazumdar, editor of Exploration Insights, shared his thoughts on how investors can differentiate between good and bad financings.

Along with considerations like warrants, he told the Investing News Network that before buying shares of an exploration company it's a good idea to look at when it last went to market.

read more Show less
Hygrovest Limited

Building a globally diversified portfolio of companies in high-growth industries.



Overview

Hygrovest Limited (ASX:HGV) has a globally diversified portfolio focused on investing in private and public companies in high-growth industries. Hygrovest has investments in cannabis-focused companies and in December 2021, the company expanded their portfolio to include healthcare, natural resources, and the digital economy as well as e-sports, sports betting, online gaming, and fintech.


Hygrovest's diversified investment is managed by Parallax Ventures Inc. (“Parallax”), a specialist management company in Canada, under a long-term strategic partnership. The agreement with Parallax offers access to new investment opportunities, added material value to existing investments, minimised HGV’s fixed cost structure, and secured meaningful investment presence in HGV’s key investment market – North America.

Hygrovest's portfolio includes a portfolio of CBD and cannabis investments in cultivation, extraction and consumer products with material investments in Weed Me, WeedMD, Sequoya, Harvest One and Southern Cannabis Holdings.

Hygrovest

Hygrovest operates a robust share purchase plan, which provides eligible shareholders the opportunity to invest in the portfolio at a 51 percent discount to net value assets. This attribute is exceptionally advantageous with the company's generation of substantial realized gains from its sale of Dosecann Inc. and Medipharm LABS, two Canadian cannabis-based companies providing leading cannabis technologies in extraction and product development.

A significant goal for Hygrovest's Board includes trading its share price at a premium to NAV, considering prospective returns from its high-quality portfolio companies. The company has seen positive trends in investment returns in the past five years and has generated a Multiple on Invested Capital (MOIC) of 1.3 times capital invested. Its mixture of private and listed companies across the emerging Australian and offshore cannabis and hemp markets primes the company for dominant standing as a major investment company.

Hygrovest Test Tube

Its highly-developed investment process includes active formulating, frequent reviewing, and effective investment best practices based on reliable valuation information. The Hygrovest Board operates as the final approval level for acquisition and the sale of investment proposals, which involve an exercise of rights attached to specific investments. Its current investment approval process operates based on Hygrovest's Investment Management Agreement with Parallax Ventures Inc, effective from 1 June 1 2019.

Future plans for the company involve focusing on U.S. investment expansion, employing liquidity into Canadian markets and developing its brands and distribution chains. The company notes significant attention towards its Harvest One Cannabis (TSXV:HVT) investee, which saw a 116 percent increase in value during February 2021, reaching totals of CAD$13.4 million.

Harvest One

"You can see with Harvest One, which is our largest investment, has a massive distribution network and has very high-quality plans coming along. We believe those types of investments in the long-term will be exceptionally attractive," commented Hygrovest Non Executive Director Michael Curtis.

Hygrovest Limited comprises a strong team with over 80 years of combined experience in investment banking, corporate strategy and cannabis fields. The company also benefits from having the Canadian-based Parallax Ventures Inc. on its Board as a strategic asset manager. Together, this leadership primes Hygrovest for significant success and growth with strategies to enhance acceleration and collaboration within the portfolio.

Company Highlights

  • Hygrovest has a globally diversified portfolio that includes private and public companies in high-growth industries.
  • Hygrovest has expanded their portfolio to include healthcare, natural resources, and the digital economy as well as e-sports, sports betting, online gaming, and fintech.
  • Investment return in the past five years has generated a MOIC of 1.1 times the capital invested. This financial upside is amplified with the company's MOIC of 3.5 times on investments sold in that period including sales of Dosecann Inc. and Medipharm LABS.
  • Hygrovest has a proven track record in acquiring and realizing significant value from its investments. They combine years of professional experience in investment banking, corporate governance and strategic acquisition.
  • Harvest One Cannabis, Hygrovest's largest investment, saw a 116 percent increase in value totaling CAD$13.4 million in February 2021, presenting the company with exceptional growth potential.
  • The company has a strong management team and benefits from having the Canadian-based Parallax Ventures Inc. on its board as its asset manager.
Weed Me

Hygrovest Limited operates a robust investment portfolio consisting of listed and private cannabis companies across a diverse variety of emerging cannabis-related sectors, including healthcare, technology, infrastructure, logistics, processing, cultivation, equipment and retail.

Current investment in its portfolio include:

  • Harvest One Cannabis Inc. (CVE:HVT)
  • Southern Cannabis Holdings
  • Weed Me
  • Martha Jane Medical
  • Vitagenne
  • Sequoya
  • WeedMD Rx Inc. (CVE:WMD)
  • Bespoke Capital Acquisition Corp.

Hygrovest 's portfolio of investments sold:

  • BevCanna Enterprises Inc. (CNSX:BEV)
  • Fire & Flower (TSE:FAF)
  • MediPharm LABS (TSE:LABS)
  • Hemple
  • Axiomm Technologies
  • Volero Brands Inc.

This portfolio leverages favorable market conditions with the majority of Canadian listed cannabis producer valuations seen dropping in 2020. Hygrovest intends to take advantage of this market backdrop and continue to create substantial investment opportunities, strategic partnerships and high-quality acquisitions.

Management Team

Peter Wall - Non- Executive Chairman

Peter Wall is a corporate lawyer and has been a partner at Steinepreis Paganin, a Perth-based corporate law firm, since July 2005. He has a wide range of experience in all forms of commercial and corporate law, with a particular focus on medical cannabis, resources, equity capital markets and mergers and acquisitions. He also has significant experience in dealing with cross-border transactions.

Wall graduated from the University of Western Australia in 1998 with a Bachelor of Laws and Bachelor of Commerce (Finance). He has also completed a Masters of Applied Finance and Investment with FINSIA.

Winton Willesee - Non-Executive Director

Winton Willesee is an experienced company director and brings a broad range of skills and experience in strategy, company development, corporate governance, company public listings, merger and acquisition transactions and corporate finance. He has considerable experience with ASX listed and other companies over a broad range of industries, having been involved with many successful ventures from early-stage through to large capital development projects.

Willesee holds formal qualifications in economics, finance, accounting, education and governance. He is a fellow of the Financial Services Institute of Australasia, a graduate of the Australian Institute of Company Directors, a member of CPA Australia and a fellow of the Governance Institute of Australia/Chartered Secretary.

Doug Halley - Non-Executive Director

Doug Halley is an experienced company director and has served for 30 years as CFO or CEO in several significant and successful commercial enterprises and investment banks. His executive experience had a heavy emphasis on corporate strategy, treasury, financial management, M&A and business development. As a professional director, Halley has developed risk management and governance expertise. He has a strong background in IPO and start-ups and a reputation for innovation, perseverance and achieving solutions and results.

Halley has a Bachelor of Commerce, Master of Business Administration and is a fellow of the Australian Institute of Company Directors.

Michael Curtis - Non-Executive Director

Michael Curtis resides in Toronto, Canada and is an experienced former investment banker and private equity executive. He is an active cannabis sector executive, having recently served as VP of Corporate Finance of Dosecann Inc. and Managing Partner of Parallax Ventures Inc. Curtis was previously the COO and Director of Embark Health Inc. and remains a consultant to Embark Health Inc.

Curtis has a Master of Business Administration from the University of New Brunswick, Bachelor of Sciences (Honors) from McMaster University.

Jim Hallam - CFO & Corporate Secretary

Jim Hallam has over 30 years of experience in the investment management industry with alternative asset fund managers in Australia and overseas, including Hastings Funds Management and Annuity Australia. His roles include acting as responsible manager, investment manager and Chief Financial Officer within alternative asset fund managers.

Hallam has a Bachelor of Commerce in Economics, is a member of the Chartered Accountants Australia and New Zealand and a fellow of the Governance Institute of Australia.

HGV:AU
silver coins
Zlaťáky.cz / Pexels

"I think that (investment demand is) going to be kind of the wild card that could really push silver much higher," said Peter Krauth of Silver Stock Investor.

Peter Krauth: Silver Price in 2022, Can Anything Derail the Metal Now? youtu.be

Peter Krauth, editor of Silver Stock Investor, has a long-term silver price target of US$300 per ounce. But what does he see coming for the white metal in 2022?

Speaking at the Prospectors & Developers Association of Canada (PDAC) convention, Krauth said he thinks a realistic move for silver this year would be "to at least US$25, or a little bit north of US$25."

In his opinion, industrial demand will create a key price floor, while investment demand will be less predictable.

read more Show less

Australia's medical cannabis market is growing, with recreational legalisation and exports presenting future opportunities for savvy investors.

Australia’s cannabis market is young, but with new products coming online, a growing push toward recreational legalisation and increased clinical research, it could offer a unique investment opportunity.

Investors are eagerly awaiting the growth projected for the Australian cannabis space — with medical avenues now established, it shows signs of potentially moving into another phase with broader access.

Read on for a look at projections for the cannabis industry in Australia and what they may mean for investors.


Investing in cannabis stocks on the ASX: Market overview

Medical cannabis was legalised in Australia in 2016, when the Narcotic Drugs Act was amended. This move allowed the plant to be grown for medical and scientific purposes, and sparked movement in the industry.

Expansion is projected moving forward. In a recent report from Grand View Research, researchers state that the legal cannabis market in Australia is poised for large increases in the coming years. Valued at AU$51.8 million in 2021, this number is projected to rise at a compound annual growth rate of 30.1 percent until 2028.

However, in recent years the country has been hit by the slump dragging down cannabis markets across the world. Among other impacts, this has brought a drastic shift in international investment, with some Canadian firms adjusting their Australian expansion plans due to the conditions seen in the cannabis industry.

Despite the struggles seen in the stock market, the Australian cannabis industry has seen some pick-up thanks to the rush of new medical cannabis products becoming available to consumers.

According to a report from cannabis research firm FreshLeaf Analytics, during H2 2021, market growth exceeded expectations, and the country's patient count climbed to near 100,000.

“Although we note the early stage of the sector in Australia and the associated volatility of a nascent industry, over the same period patient numbers domestically have continued to soar,” the note explains.

The rise in patient approvals could be due to legislation put in place in New South Wales that loosened the requirements for prescribing medical cannabis. Now, unless a patient is under 16 years old or has a history of drug abuse, medical practitioners in the state can prescribe cannabis medicines without having to refer to a specialist.

There’s also been a decrease in pricing pressure for medical cannabis patients throughout the country, which is helping to boost access for consumers. FreshLeaf states that monthly spending from medical cannabis patients was down to AU$395 in 2019 from AU$415, and has since further dropped to AU$278.

Investing in cannabis stocks on the ASX: Avenues for growth

As Australia's medical cannabis market grows, other avenues for expansion are also opening.

Australia has seen an increased push to okay cannabis for recreational use since the Australian Capital Territory announced plans to legalise the drug in September 2019; it was the first region in the country to do so.

The new law came into effect on January 31, 2020, and allows individuals over 18 to possess up to 50 grams of dried flower and cultivate two cannabis plants in their home, with a maximum of four plants per residence.

However, no stores sell it, and the only legal means to acquire cannabis in the state is to personally grow it.

The Hemp Industry Act (2019), allows commercial uses of the hemp plant, and a bill was introduced in February 2021 by Cate Faehrmann that would legalise cannabis products in New South Wales.

Cannabis exports may also be a bright spot — shipping the drug out of the country was legalised in 2018, and top markets now include countries like Germany, the UK and South Africa.

Notably, Australia has expressed its desire to become one of the largest international cannabis suppliers. Back in 2018, former Health Minister Greg Hunt said, “We’d like to be potentially the world’s number one supplier.”

A 2020 report from Prohibition Partners forecasts that medical cannabis in the Oceania region, which includes Australia, could be worth US$600 million by 2024, while recreational cannabis could rake in US$1.55 billion.

The report also says that, despite the double-digit fall of cannabis stock prices in Australia (attributed partially to the COVID-19 pandemic), production and supply lines for the local cannabis industry have been maintained.

Peter Comerford, CEO of Australia healthcare product wholesaler Anspec, said the country is in a solid position to “capitalise on whichever aspects of this new industry that it chooses.”

Investing in cannabis stocks on the ASX: How to get started

The universe of ASX-listed cannabis stocks is small, but there are certainly options for investors willing to do a little research. To get started, check out these lists on the topic:

Investing in cannabis stocks on the ASX: Investor takeaway

Though Australia's cannabis industry is still in its early stages, increased patient numbers and a push toward recreational cannabis use could open the market to novel investment opportunities.

The nation's expanding cannabis export space could also further the growth of its place in the global cannabis market. For now, there's time for interested investors to get in early and gain a toehold.

This is an updated version of an article first published by the Investing News Network in 2019.

Don’t forget to follow us @INN_Australia for real-time news updates!

Securities Disclosure: I, Ryan Sero, hold no direct investment interest in any company mentioned in this article.

gold coins and us money
nyker / Shutterstock

Is there more upside right now for gold or the US dollar? "I think clearly I'm in the camp of favoring gold on that one," said Will Rhind of GraniteShares.

Will Rhind: Upside Favors Gold; Strong US Dollar Checking Gains for Now youtu.be

Strength in the US dollar is keeping the gold price in check right now, but that won't last forever.

Speaking to the Investing News Network, Will Rhind, CEO of GraniteShares, said the yellow metal is in a good position given market conditions and looks set to strengthen moving forward.

"(Gold has) really managed to shrug off a lot of the negatives around rising rates and a strong dollar, and I think people have got to ask themselves, 'How much more can the dollar strengthen from here? ... Realistically is there more upside for the dollar here, or for gold?' I think clearly I'm in the camp of favoring gold on that one," he said.

read more Show less
Hygrovest



Hygrovest Limited (ASX:HGV) ("HGV") is an Australian-listed specialist investment company which concentrates on producing capital growth for shareholders over the medium term from investments in listed and unlisted equities and other financial assets.

HGV agrees to divest its investment in Entourage Health above current book value

HGV has agreed to support proposed changes to the terms of the unsecured convertible debentures issued by Entourage Health Corp (ENT or the Company) which would allow HGV to divest its investment in ENT convertible debentures (the Notes).

The attached release by ENT details the changes proposed by the Company which would allow HGV to complete the divestment of ENT which bring forward the maturity date from 25 September 2022 to 30 June 2022 and reduce the redemption percentage from 100% to 60% of face value (the Note Proposals).

The Company has announced that a meeting of ENT Noteholders will be held in late June 2022 to consider the Note Proposals. HGV has signed a voting agreement to vote in favour of the changes. If the meeting of ENT Noteholders approves the amendments, ENT will redeem HGV’s Notes for CAD3.6m plus accrued interest on or around 30 June 2022 which is a premium to HGV’s book value of CAD2.5m as at 30 April 2022.

On the basis that ENT Noteholders approve the resolutions, HGV will have generated a loss of 18% on the original investment (after inclusion of cash interest received). Whilst the investment in HGV’s Notes has been well below expectations at the time of initial investment, it should be noted that the return is materially above that for the listed Canadian cannabis sector which has declined approximately 70%1 since January 2020.

The divestment was negotiated by HGV’s asset manager, Parallax Ventures Inc, on behalf of HGV.

“The divestment of HGV’s investment in ENT at a significant premium to our book value is an important step in realising HGV’s underperforming cannabis investments and applying those funds to sectors which have higher growth prospects” said Mr Wall, HGV’s Chairman.

HGV made its initial investment in ENT in September 2019 and now has a current book value of CAD2.5m comprising:

  1. CAD6m in 8.5% unsecured Convertible Debenture units issued by ENT which HGV has the option to convert into 3.75m shares by the maturity date of 25 September 2022. The debenture units have preference over ordinary shares with interest paid to HGV on a six-monthly basis. The market value of the notes is calculated by multiplying the CAD6m by the market price divided by 100.
  2. Listed Warrants that allow HGV to acquire an additional 3.75m shares for CAD1.80 each by 25 September 2022.
About HGV

Hygrovest Limited (ASX:HGV) ("HGV") (ABN 91 601 236 417) is an Australian-listed specialist investment company which concentrates on producing capital growth for shareholders over the medium term from investments in listed and unlisted equities and other financial assets.

Important Notice

This announcement contains reference to certain intentions, expectations, future plans, strategy and prospects of HGV. Those intentions, expectations, future plans, strategy and prospects may or may not be achieved. They are based on certain assumptions, which may not be met or on which views may differ and may be affected by known and unknown risks. The performance and operations of HGV may be influenced by a number of factors, many of which are outside the control of HGV. No representation or warranty, express or implied, is made by HGV, or any of its directors, officers, employees, advisers or agents that any intentions, expectations or plans will be achieved either totally or partially or that any particular rate of return will be achieved. Given the risks and uncertainties that may cause HGV’s actual future results, performance or achievements to be materially different from those expected, planned or intended, recipients should not place undue reliance on these intentions, expectations, future plans, strategy and prospects. HGV does not warrant or represent that the actual results, performance or achievements will be as expected, planned or intended. Nothing in this material should be construed as either an offer to sell or a solicitation of an offer to buy or sell securities. It does not include all available information and should not be used in isolation as a basis to invest in HGV. This document does not constitute any part of any offer to sell, or the solicitation of an offer to buy, any securities in the United States or to, or for the account or benefit of any “US person” as defined in Regulation S under the US Securities Act of 1993 (“Securities Act”). HGV’s shares have not been, and will not be, registered under the Securities Act or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold in the United States or to any US person without being so registered or pursuant to an exemption from registration including an exemption for qualified institutional buyers.

This article includes content from Hygrovest Limited (ASX:HGV), licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.
HGV:AU

General Manager Matt Herbert described Ontario as an “undiscovered gem,” and spoke about the company’s work on its lithium projects in the province.


After making its ASX debut this past November, Green Technology Metals (ASX:GT1) has been hard at work in Ontario, Canada, where it holds three projects covering 35,000 hectares.

Speaking to the Investing News Network at the Prospectors & Developers Association of Canada (PDAC) convention, General Manager Matt Herbert described the province as an “undiscovered gem” with the potential to contribute to the lithium supply chain in an environmentally conscious manner.

“I think the opportunity there is to create some very, very green lithium,” he said.


“At the moment, a lot of lithium is mined in Western Australia, (then) shipped to China for processing; from China it goes to European battery markets. I think by the time that lithium arrives where it’s supposed to arrive it’s left itself a bit of a carbon footprint,” Herbert explained during the conversation. “We have a real opportunity here to leverage low-carbon lithium in a place that is really screaming for security.”

Green Technology Metals has already seen support from members of the Ontario government, including recently re-elected Premier Doug Ford, and Greg Rickford, who is the province’s minister of northern development, mines, natural resources and forestry, as well as its minister of indigenous affairs.

“Both are massive supporters of critical minerals,” said Herbert. “Those things are important when you’re at the permitting and approval stage, and that’s exactly where we’re at. We’re able to leverage those relationships really well, and there’s just no better place to be at the moment.”

Watch the interview above for more from Herbert on Green Technology Metals and its plans for the next six months. You can also click here for our recap of PDAC, and here for our full PDAC playlist on YouTube.

Don’t forget to follow us @INN_Australia for real-time updates!

Securities Disclosure: I, Charlotte McLeod, hold no direct investment interest in any company mentioned in this article.

Editorial Disclosure: Green Technology Metals is a client of the Investing News Network. This article is not paid-for content.

The Investing News Network does not guarantee the accuracy or thoroughness of the information reported in the interviews it conducts. The opinions expressed in these interviews do not reflect the opinions of the Investing News Network and do not constitute investment advice. All readers are encouraged to perform their own due diligence.

electric vehicle charging
Blue Planet Studio / Shutterstock

General Manager Matt Herbert described Ontario as an "undiscovered gem," and spoke about the company's work on its lithium projects in the province.

Green Technology Metals: Cashed Up and Pursuing Low-carbon Lithium in Ontario youtu.be

After making its ASX debut this past November, Green Technology Metals (ASX:GT1) has been hard at work in Ontario, Canada, where it holds three projects covering 35,000 hectares.

Speaking to the Investing News Network at the Prospectors & Developers Association of Canada (PDAC) convention, General Manager Matt Herbert described the province as an "undiscovered gem" with the potential to contribute to the lithium supply chain in an environmentally conscious manner.

"I think the opportunity there is to create some very, very green lithium," he said.


"At the moment, a lot of lithium is mined in Western Australia, (then) shipped to China for processing; from China it goes to European battery markets. I think by the time that lithium arrives where it's supposed to arrive it's left itself a bit of a carbon footprint," Herbert explained during the conversation. "We have a real opportunity here to leverage low-carbon lithium in a place that is really screaming for security."

Green Technology Metals has already seen support from members of the Ontario government, including recently re-elected Premier Doug Ford, and Greg Rickford, who is the province's minister of northern development, mines, natural resources and forestry, as well as its minister of indigenous affairs.

"Both are massive supporters of critical minerals," Herbert said. "Those things are important when you're at the permitting and approval stage, and that's exactly where we're at. We're able to leverage those relationships really well, and there's just no better place to be at the moment."

Watch the interview above for more from Herbert on Green Technology Metals and its plans for the next six months. You can also click here for our recap of PDAC, and here for our full PDAC playlist on YouTube.

Don't forget to follow us @INN_Australia for real-time updates!

Securities Disclosure: I, Charlotte McLeod, hold no direct investment interest in any company mentioned in this article.

Editorial Disclosure: Green Technology Metals is a client of the Investing News Network. This article is not paid-for content.

The Investing News Network does not guarantee the accuracy or thoroughness of the information reported in the interviews it conducts. The opinions expressed in these interviews do not reflect the opinions of the Investing News Network and do not constitute investment advice. All readers are encouraged to perform their own due diligence.

GT1:AU

Top News

Global News

×